Carbon-ion radiotherapy achieved 91% two-year local control in limited-stage SCLC
In 39 patients, carbon-ion RT achieved 91.2% two-year local control without grade ≥3 acute radiation-associated toxicity.
Tag
sclc
Omitting CTV reduced toxicity without compromising outcomes in limited-stage SCLC
After matching 530 patients, CTV omission preserved survival and recurrence patterns while substantially reducing pneumonitis and esophagitis.
Memory-network avoidance PCI was feasible beyond hippocampal sparing in limited-stage SCLC
VMAT-based PCI spared additional memory-network structures while maintaining whole-brain coverage in two patients with limited-stage SCLC.
SBRT timing relative to chemotherapy did not affect survival in stage I SCLC
Stage I SCLC survival was similar whether SBRT preceded chemotherapy or was delivered after chemotherapy had started.
ELCC 2026 highlights expanding roles for radiotherapy across modern thoracic oncology
ELCC 2026 highlighted growing integration of SBRT and thoracic radiotherapy with targeted therapy, immunotherapy and biomarker-guided treatment selection.
SRT did not improve survival over whole-brain radiotherapy after matching in SCLC
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
Twice-daily radiotherapy was associated with longer survival in younger limited-stage small cell lung cancer
Among patients under 70, twice-daily chemoradiotherapy was associated with 36.0 versus 22.2 months median survival, without higher acute toxicity.
Thoracic radiotherapy with atezolizumab increased toxicity in extensive-stage small cell lung cancer
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.